RiboTargets is a privately owned pharmaceutical drug discovery company focused on the development of novel anti-bacterial and anti-cancer therapeutics. These therapeutic areas represent significant market opportunities. The Company has created and validated a proprietary structure-based drug discovery engine that allows the rapid identification and optimisation of drug candidates against both protein and nucleic acid targets using high throughput computer-aided and experimental drug design. Over the last four years, RiboTargets has made the transition from a technology platform company into a competitive drug discovery company. RiboTargets' goal for 2003 is to make the pivotal step from research into formal drug development. In the longer term, RiboTargets aims to become a significant player in the anti-bacterial and anti-cancer markets.
